ARQT
vs
S&P 500

Over the past 5 years, ARQT has underperformed S&P 500, delivering a return of -33% compared to the S&P 500's 83% growth.

Stocks Performance
ARQT vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
ARQT vs S&P 500

Performance Comparison
ARQT vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
ARQT
Arcutis Biotherapeutics Inc
18%
49%
40%
261%
-33%
-33%
-33%
S&P 500
Market Index
-2%
4%
7%
25%
83%
197%
400%

Arcutis Biotherapeutics Inc
Glance View

Market Cap
1.7B USD
Industry
Biotechnology

Arcutis Biotherapeutics Inc. emerged on the biopharmaceutical scene with a focused mission: to redefine how common yet undertreated dermatological conditions are managed. Founded in California, this innovative company is dedicated to advancing treatments for wide-ranging skin diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis sets itself apart by concentrating on developing topical treatments, appreciating both the nuanced challenges of dermatological conditions and the substantial unmet needs in this field. The company's research and development efforts pivot around creating therapies that deliver both efficacy and safety, making them suitable for chronic use without the concerning side effects that often accompany existing treatments. Arcutis generates its revenue primarily through the successful development and subsequent commercialization of its product pipeline. By harnessing cutting-edge scientific platforms and fostering strategic collaborations, the company aims to accelerate the transition of its promising candidates from the lab to the marketplace. Revenue streams are expected to be bolstered through product sales and potentially through partnerships or licensing arrangements with larger pharmaceutical players. By addressing specific pain points within dermatology, particularly in the realm of topical applications, Arcutis is strategically positioning itself to capture significant market share in a landscape where effective solutions are in high demand yet remain limited.

ARQT Intrinsic Value
16.31 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

Back to Top